TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A 2026 paper in The Lancet Healthy Longevity argues that sarcopenia and age-related mobility loss should be understood as problems involving the whole motor system, not muscle alone. The authors propose changes to research and clinical assessment, but say new measures have not yet been shown to improve outcomes or reduce costs.
Researchers writing in The Lancet Healthy Longevity argue that age-related weakness and loss of mobility should be understood as problems of the whole motor system, not muscle alone. Their proposed reframing could affect how clinicians assess older adults and how researchers design treatments, but the authors say the suggested assessment measures still need validation.
The paper, by Lucas B. R. Orssatto and colleagues, challenges the common explanation that weakness in older adults mainly results from muscle wasting. Sarcopenia is associated with declining muscle, strength and physical function, but the authors say the amount of muscle lost explains only a modest share of the reduction in strength. People with similar muscle mass can also have different levels of strength and mobility.
The authors describe the motor system as the processes involved in producing movement, from the brain and spinal cord through nerves and their connections to muscle. Aging can affect movement planning, signal transmission, balance and position sense, they argue, so a person may have difficulty using existing muscle effectively. The paper points to chair rises as an example: getting up quickly depends on power and nerve-driven muscle recruitment, not just muscle bulk.
They propose that clinicians continue measuring strength and walking speed while also observing how quickly a patient rises from a chair, whether they appear unsteady during sustained effort, and whether hand dexterity or walking changes when the person talks at the same time. The authors also recommend closer examination of weakness that is asymmetric, rapid or disproportionate to apparent muscle loss, and say medication review should be considered because sedatives and anticholinergic drugs can blunt motor drive.
A Broader View of Mobility Loss
The argument matters because mobility affects independence, and falls can cause serious injury and require hospital care. The Medical Xpress report says sarcopenia affects up to 29% of older adults living in the community, with higher rates in settings such as hospitals and residential care and among people with frailty or multiple health conditions.
In Australia, falls remain a major health burden: the report cites 253,800 fall-related hospitalizations in 2024–25 and 6,722 deaths following falls in the preceding year. It also reports an estimated $5.4 billion in health-system costs from fall injuries. These figures describe the broader consequences of falls; they do not show that the proposed motor-system approach would prevent them.
The paper’s reframing could redirect research beyond treatments that increase muscle mass toward approaches that target strength and everyday function. That is a proposal, not evidence that existing muscle-building treatments are ineffective or that a new strategy has already improved patient outcomes. The authors say trials should measure nerve function as well as muscle and test whether proposed clinical measures are useful.
Products Worth Considering
Bowflex SelectTech 840 Adjustable Kettlebell
BowFlex Results Series SelectTech 552 Adjustable Dumbbell
Theragun Mini 3rd Generation Massage Gun – Travel Essential (Black)
As an affiliate, we earn on qualifying purchases.
How Sarcopenia Assessment Has Shifted
Clinical definitions have already moved away from relying on muscle mass alone. The report says grip strength, gait speed and chair stands are used to assess sarcopenia because these measures can better predict outcomes such as falls, disability and death than muscle mass by itself. The authors’ criticism is that the explanation of the condition has not kept pace with this change in measurement.
Australian primary care practices have also been given a proposed algorithm for screening, assessing and managing poor muscle health. The Australian Journal of General Practice published the proposal earlier in 2026, according to Medical Xpress. The new paper adds a challenge to the underlying framework: if everyday function is the concern, assessment may need to account for the nerves and other systems that help produce movement.
The publication is an argument and research agenda, not a replacement clinical guideline. Its authors propose a five-point agenda for international groups that set diagnostic criteria, including practical tests and research that considers the motor system as a whole. The supplied report does not list all five points individually.
“We propose that sarcopenia is better understood as a disease of the aging motor system.”
— Lucas B. R. Orssatto and co-authors, in The Lancet Healthy Longevity
Tests and Benefits Still Unproven
The authors say it is not yet known whether the proposed measures outperform existing screening approaches on patient outcomes or cost. The supplied report does not describe a clinical trial testing the approach, or evidence that adopting it reduces falls, disability or loss of independence.
The authors call for practical tests and note that neuromuscular expertise is unevenly available. The article does not provide detailed results from a trial of medication review or specify which patients would benefit most from additional assessment.
The proposed reframing should therefore be read as a research and clinical framework under discussion, not as proof that muscle-focused care should be stopped. Further research is needed to establish which parts of the motor system can be assessed consistently and whether addressing them leads to better outcomes.
Validation Before Clinical Change
The authors call for investment in validating practical tests that clinicians can use, guidelines that support a staged assessment, and trials that measure nerve function alongside muscle. Those steps could help determine whether a broader assessment identifies meaningful differences among patients and whether the findings can guide care.
International working groups responsible for sarcopenia diagnostic criteria are a proposed audience for the paper’s agenda. The supplied report does not identify a timetable for changes to diagnostic standards or announce a new guideline. For now, the next milestone is evidence showing whether the proposed approach is feasible and improves outcomes compared with existing screening.
Key Questions
What is the paper’s main argument?
The authors argue that age-related weakness and mobility loss involve the whole motor system, including the brain, spinal cord and nerves, as well as muscle. They say muscle loss alone does not explain much of the decline in strength.
Does this change the current definition of sarcopenia?
No change to diagnostic standards is reported. The paper proposes a broader way to understand sarcopenia and calls on international groups to consider its recommendations.
What additional signs do the researchers suggest observing?
They suggest noting how quickly someone rises from a chair, balance during sustained effort, hand dexterity and changes in walking while talking. The authors say these measures need further validation.
Has the proposed approach been shown to prevent falls?
No. The authors say the new measures have not been shown to outperform existing screens on outcomes or cost. The report does not present evidence that this approach reduces falls or disability.
Source: medicalxpress.com
